Cargando…

Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

We evaluated the efficacy and safety of pembrolizumab in patients from Asia with previously treated advanced hepatocellular carcinoma (HCC). METHODS: In a double-blind, phase III trial, 453 patients with advanced HCC and progression during or after treatment with or intolerance to sorafenib or oxali...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Shukui, Chen, Zhendong, Fang, Weijia, Ren, Zhenggang, Xu, Ruocai, Ryoo, Baek-Yeol, Meng, Zhiqiang, Bai, Yuxian, Chen, Xiaoming, Liu, Xiufeng, Xiao, Juxiang, Ho, Gwo Fuang, Mao, Yimin, Wang, Xin, Ying, Jieer, Li, Jianfeng, Zhong, Wenyan, Zhou, Yu, Siegel, Abby B., Hao, Chunyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2023
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995104/ https://www.ncbi.nlm.nih.gov/pubmed/36455168 http://dx.doi.org/10.1200/JCO.22.00620

Ejemplares similares

Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial
por: Wang, Feng, et al.
Publicado: (2020)

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
por: Qin, Shukui, et al.
Publicado: (2021)

Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment
por: Llovet, Josep M., et al.
Publicado: (2022)

Palbociclib in the treatment of recurrent ovarian cancer
por: Lee, Dai Wee, et al.
Publicado: (2020)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021)

A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma
por: Von, Cheong E, et al.
Publicado: (2021)

Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study
por: Li, Hui, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
por: Liu, Xiufeng, et al.
Publicado: (2019)

Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial
por: Verset, Gontran, et al.
Publicado: (2022)

Radiation Oncology Research in Asia: Current Status and a Peep Into the Future From the Federation of Asian Organizations for Radiation Oncology
por: Chopra, Supriya, et al.
Publicado: (2023)

Pembrolizumab
por: Khoja, Leila, et al.
Publicado: (2015)

SUN-412 A Unique Case of Isolated ACTH Deficiency Caused by Pembrolizumab
por: Erenler, Feyza, et al.
Publicado: (2019)

Pembrolizumab in Asia‐Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE‐012
por: Tahara, Makoto, et al.
Publicado: (2018)

Childbirth Pain, Labor Epidural Analgesia, and Postpartum Depression: Recent Evidence and Future Directions
por: Du, Weijia, et al.
Publicado: (2022)

Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia
por: How, Soon Hin, et al.
Publicado: (2022)

ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240
por: Vogel, Arndt, et al.
Publicado: (2021)

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
por: Finn, Richard S., et al.
Publicado: (2020)

Exploring Unmet Needs from an Online Metastatic Breast Cancer Support Group: A Qualitative Study
por: Kadravello, Aravinthan, et al.
Publicado: (2021)

Pembrolizumab for all
por: Kim, Myung S., et al.
Publicado: (2022)

Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy
por: Murakami, Shuji, et al.
Publicado: (2020)

Discrepancy in patient-rated and oncologist-rated performance status on depression and anxiety in cancer: a prospective study protocol
por: Mei Hsien, Caryn Chan, et al.
Publicado: (2012)

Into the Clinic With Nivolumab and Pembrolizumab
por: Shu, Catherine A., et al.
Publicado: (2016)

Pembrolizumab-associated sarcoidosis
por: Cotliar, Jonathan, et al.
Publicado: (2016)

Pembrolizumab-induced pneumonitis
por: Leroy, Vincent, et al.
Publicado: (2017)

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
por: Mimura, Kaito, et al.
Publicado: (2022)

The Emerging Role of Neutrophil Extracellular Traps in Arterial, Venous and Cancer-Associated Thrombosis
por: Zhou, Yilu, et al.
Publicado: (2021)

Comparison of Prophylactic Norepinephrine and Phenylephrine Infusions During Spinal Anaesthesia for Primary Caesarean Delivery in Twin Pregnancies: A Randomized Double-Blinded Clinical Study
por: Du, Weijia, et al.
Publicado: (2022)

Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response
por: Kang, Junho, et al.
Publicado: (2020)

Renal toxicities associated with pembrolizumab
por: Izzedine, Hassan, et al.
Publicado: (2018)

Pembrolizumab reactivates pulmonary granulomatosis
por: Al-dliw, Majdi, et al.
Publicado: (2017)

Pembrolizumab-induced bullous pemphigoid
por: Sun, Christina W., et al.
Publicado: (2019)

Pembrolizumab microgravity crystallization experimentation
por: Reichert, Paul, et al.
Publicado: (2019)

Association of Celiac Disease With Pembrolizumab
por: Sethi, Ashish, et al.
Publicado: (2021)

Molecular Farming of Pembrolizumab and Nivolumab
por: Stark, Michael C., et al.
Publicado: (2023)

Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression
por: Ryoo, Baek-Yeol, et al.
Publicado: (2021)

Dual targeted therapy with pyrotinib and trastuzumab for HER2‐positive advanced colorectal cancer: A phase 2 trial
por: Fu, Xianhua, et al.
Publicado: (2022)

Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study
por: Chen, Song, et al.
Publicado: (2021)

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial
por: Merle, Philippe, et al.
Publicado: (2023)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

Human Migration through Bottlenecks from Southeast Asia into East Asia during Last Glacial Maximum Revealed by Y Chromosomes
por: Cai, Xiaoyun, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ob202jk494s1886psdpae0j9sq